Hilde Rosing

The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria

Johan W. Jonker, Marije Buitelaar, Els Wagenaar et al. · Proceedings of the National Academy of Sciences · 2002 · 821 citations · Full text

Medicine, Oncology, Toxicology +14

Stable isotopically labeled internal standards in quantitative bioanalysis using liquid chromatography/mass spectrometry: necessity or not?

Ellen Stokvis, Hilde Rosing, Jos H. Beijnen · Rapid Communications in Mass Spectrometry · 2005 · 576 citations

Natural Sciences, Biochemistry, Chemistry +17

Increased Oral Bioavailability of Topotecan in Combination With the Breast Cancer Resistance Protein and P-Glycoprotein Inhibitor GF120918

C.M.F. Kruijtzer, Jos H. Beijnen, Hilde Rosing et al. · Journal of Clinical Oncology · 2002 · 462 citations

Pharmacy, Pharmacokinetics, Pharmacology +13

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

Linda M. Henricks, Carin A.T.C. Lunenburg, Femke M. de Man et al. · The Lancet Oncology · 2018 · 419 citations · Full text

Medicine, Oncology, Pharmacology +16

Upfront Genotyping of <i>DPYD</i>*<i>2A</i> to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis

Maarten J. Deenen, Didier Meulendijks, Annemieke Cats et al. · Journal of Clinical Oncology · 2015 · 345 citations · Full text

Medicine, Oncology, Pharmacology +17